Age-related differences in adverse events among vericiguat-treated patients with heart failure: insights from the VERIFY-HF registry
Vericiguat improves outcomes in patients with worsening heart failure with reduced ejection fraction (HFrEF). However, its safety profile in very elderly patients remains poorly characterized in routine clinical practice, where multimorbidity and renal dysfunction are prevalent. We aimed to evaluate age-related d...